Skip to main content
Philogen logo

Philogen — Investor Relations & Filings

Ticker · PHIL ISIN · IT0005373789 LEI · 81560009EA1577917768 XMIL Manufacturing
Open in API
Filings indexed 375 across all filing types
Latest filing 2026-03-30 Proxy Solicitation & In…
Country IT Italy
Listing XMIL PHIL

About Philogen

https://www.philogen.com

Philogen is a clinical-stage biotechnology company focused on the discovery and development of novel biopharmaceutical products for the treatment of cancer and other serious conditions associated with angiogenesis. Founded in 1996, the company's core strategy is based on innovating targeted therapies, such as antibody-cytokine fusions, which are designed to selectively deliver therapeutic agents to the site of disease. This approach aims to increase efficacy while reducing toxicity. Philogen operates as an integrated company with capabilities in research, GMP manufacturing, and clinical development of its proprietary product pipeline.

Recent filings

Filing Released Lang Actions
Relazione illustrativa del Consiglio di Amministrazione sul terzo punto all’ordine del giorno dell’Assemblea degli Azionisti
Proxy Solicitation & Information Statement Classification · 87% confidence The document is an “explanatory report” (‘relazione illustrativa’) prepared by the Board of Directors for item 3 of the agenda of the ordinary shareholders’ meeting (“Assemblea Ordinaria”) to request shareholder approval for a dividend distribution. It is not the final dividend notice, dividend payment announcement, or AGM minutes/results, but rather part of the materials sent to shareholders in advance of the vote. This matches the definition of a proxy solicitation/information statement (Code: PSI).
2026-03-30 Italian
Relazione illustrativa del Consiglio di Amministrazione sul primo e secondo punto all’ordine del giorno dell’Assemblea degli Azionisti
Proxy Solicitation & Information Statement Classification · 95% confidence The document is the board of directors’ ‘relazione illustrativa’ under Art. 125-ter of the Italian TUF and Art. 84-ter CONSOB regs, addressed to shareholders ahead of the Ordinary Shareholders’ Meeting on 29 April 2026. It outlines proposals on the financial statements and profit allocation and solicits shareholder votes. This aligns with a Proxy Solicitation & Information Statement rather than the full annual report or AGM slide deck. Therefore, this is classified as PSI.
2026-03-30 Italian
Avviso di convocazione dell'Assemblea Ordinaria degli Azionisti
Proxy Solicitation & Information Statement Classification · 99% confidence The document is the official notice of convocation of the Ordinary Shareholders’ Meeting (Assemblea Ordinaria), including the agenda, participation and proxy voting instructions, record dates, and procedural details. It is clearly a solicitation of proxies and an information statement to shareholders ahead of the AGM. Therefore, it falls under the Proxy Solicitation & Information Statement category (PSI).
2026-03-27 Italian
The Board of Directors approves the draft financial statements and the consolidated financial statements as of december 31st, 2025 (courtesy translation) (Price sensitive)
Earnings Release Classification · 87% confidence The document is a press release issued by the Board of Directors announcing and detailing the company’s full‐year financial results for the period ended December 31, 2025. It contains key highlights—net profit, revenue, EBITDA, dividend proposal—and commentary on the results, but it is not the full statutory annual report (10‐K) with all notes, nor merely an announcement of report publication (RPA). Hence, it best fits an Earnings Release (ER). FY 2025
2026-03-27 English
Il Consiglio di Amministrazione approva il Progetto di Bilancio di Esercizio e il bilancio consolidato al 31 dicembre 2025 (Price sensitive)
Earnings Release Classification · 85% confidence The document is a press release (“Comunicato Stampa”) in Italian announcing that the Board of Directors has approved the year‐end 2025 financial statements and consolidated financials, summarizing key financial metrics (net profit, revenues, EBITDA, net financial position), and proposing items for the upcoming shareholders’ meeting (including dividend distribution). It is not the full Annual Report (10‐K) itself nor a simple notice of report publication, but rather the public announcement of the annual results in press‐release form. This matches an Earnings Release (ER). FY 2025
2026-03-27 Italian
2026 09 03 - CS settimanale acquisto azioni proprie
Transaction in Own Shares Classification · 100% confidence The document is a press release from Philogen S.p.A. titled 'AGGIORNAMENTO SUL PROGRAMMA DI ACQUISTO DI AZIONI PROPRIE' (Update on the share buyback program). It details the number of shares purchased, the average price, and the total value of transactions over a specific period (March 2-6, 2026), including a detailed table of individual transactions. This falls directly under the definition of 'Transaction in Own Shares' (POS).
2026-03-09 Italian

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.